Drug Interaction Report

Consumer information for this interaction is not currently available.

GENERALLY AVOID: Coadministration with vimseltinib may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) efflux transporter. The proposed mechanism, based on in vitro data, involves decreased clearance due to inhibition of P-gp by vimseltinib. Based on model-informed drug interaction studies, coadministration of the P-gp substrate dabigatran with vimseltinib (30 mg twice weekly) is predicted to increase the systemic exposure (AUC) and peak plasma concentration (Cmax) of dabigatran by 2 to 3-fold. However, if dabigatran is administered 4 hours after vimseltinib (30 mg twice weekly), the AUC and Cmax are predicted to increase by only up to 1.3-fold. Clinical data are not available.

MANAGEMENT: Concomitant use of vimseltinib with P-gp substrates should generally be avoided. If coadministration is considered necessary, vimseltinib should be taken at least 4 hours prior to the P-gp substrate. The individual product labeling of the P-gp substrate should be consulted for further guidance.

Food decreases the levels of erythromycin in your body. Take erythromycin on an empty stomach at least 30 minutes before or 2 hours after a meal. This will make it easier for your body to absorb the medication. However, some erythromycin products may be taken without regard to meals. Ask your healthcare provider about your particular prescription if you are uncertain of how to take it. Grapefruits and grapefruit juice may increase erythromycin levels but how this may affect you is not known. Do not increase or decrease the amount of grapefruit products in your diet without first talking to your doctor.

Information for this minor interaction is available on the professional version.